Maple Boxelder Allergy Shots: The Combined Sapindaceae Prescription for Spring Tree Allergy
Maple-boxelder allergy shots combine wind-pollinated box-elder (the dominant Acer clinical driver) with mixed-pollination true maples in a single Sapindaceae SCIT prescription — the standard clinical approach when both species contribute to spring tree allergy. No FDA-standardized Acer extract exists and no SCIT RCT has been published for any maple species, yet Dales et al.
Maple Boxelder Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to maple boxelder — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of maple boxelder allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of maple boxelder immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of maple boxelder extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for maple boxelder allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing maple boxelder extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription maple boxelder immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat maple boxelder allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Maple Boxelder?
The biology, taxonomy, and clinical fingerprint of Maple Boxelder — the foundation of how SCIT targets it.
Box-elder (Acer negundo) is dioecious and fully wind-pollinated — unlike most other maples — making it by far the dominant clinical driver in the maple-boxelder combined preparation. The mix captures both the wind-pollinated and mixed-pollination Acer exposure profiles.
- Scientific name
- Acer spp. (mixed) + Acer negundo (box-elder)
- Family
- Sapindaceae (formerly Aceraceae; APG IV reclassification)Maple family
- Type
- Combined spring tree pollen — wind-pollinated box-elder + mixed-pollination maples
- Native to
- Eastern and central North America (native Acer); box-elder naturalized to western riparian zones
- Allergen proteins
- No WHO/IUIS-named allergen for any Acer species including A. negundo, A. rubrum, A. saccharum, A. saccharinum as of May 2026Multiple IgE-binding bands documented by Western blot for box-elder pollen extractsPan-tree pollen cross-reactive proteins (profilins, polcalcins) likely present but uncharacterized
- Particle size
- Maple pollen: 22–51 × 20–36 µm depending on species
- Avoidance difficulty
- Very difficult
How Maple Boxelder Allergy Presents
Symptoms by body system — useful for distinguishing Maple Boxelder sensitivity from overlapping allergies and infections.
Respiratory
- Spring rhinitis from March through May during combined Acer pollen peak
- Asthma exacerbations — Dales et al. (2008) documented box-elder/maple pollen counts correlating with severe asthma hospitalizations in Canadian cities
- Nasal congestion and sneezing coinciding with box-elder flowering in late April to early May
- Chronic sinusitis flares during extended spring maple season in heavily sensitized patients
Ocular
- Allergic conjunctivitis coinciding with spring maple pollen peak
- Eye itching and tearing during late April–early May box-elder peak
- Periorbital swelling in heavily sensitized patients during high-pollen-count spring days
Dermal
- Atopic dermatitis flares coinciding with spring maple-boxelder pollen season
- Rare contact urticaria in patients with very high sensitization levels working in maple-heavy forested areas
- Skin symptoms typically less prominent than respiratory and ocular presentation
Systemic
- Fatigue and cognitive impairment from seasonal spring allergic disease
- Missed work and school days during heavy maple-boxelder pollen periods in the Midwest and Mid-Atlantic
- Sleep disruption from nocturnal rhinitis during the March–May spring peak
Box-elder gives you the wind-driven exposure; red maple covers the local insect-and-wind mixed component. Pooling them is a pragmatic mix — but it only matters when box-elder is in season, which is the back half of April. The incomplete intra-Acer cross-reactivity from box-elder is the clinical reason we can't simply substitute a single-species maple preparation for patients who live along box-elder-lined watercourses.
When & Where Maple Boxelder Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through mid-May (box-elder dominant); earlier March–April for true maples (silver, red)· ~8 weeks of significant combined Sapindaceae pollen exposure across the full Acer flowering season
US Exposure Map
11 high-intensity statesWhat Maple Boxelder Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Intra-Acer cross-reactivity is high but incomplete — box-elder sensitized patients react broadly to red and silver maple, but the reverse is not always complete. This asymmetric cross-reactivity is the primary clinical reason a combined preparation is preferred over single-species prescriptions.
Core mix component — dioecious, fully wind-pollinated, dominant clinical driver; asymmetric cross-reactivity (box-elder patients react to other Acer; reverse is incomplete)
Is SCIT Right for Your Maple Boxelder Allergy?
Answer 5 questions to determine whether combined maple-boxelder SCIT is the appropriate spring tree immunotherapy strategy for your allergy profile.
How severe are your spring tree pollen symptoms during the late April–May box-elder/maple peak?
The Maple Boxelder SCIT Protocol
Maple-boxelder SCIT follows standard non-standardized tree pollen build-up with box-elder as the dominant component by potency, supplemented by red or silver maple extract to cover the incomplete intra-Acer cross-reactivity.
Weekly escalation from most dilute (1:100,000) to maintenance concentration. Box-elder's asymmetric cross-reactivity means this component is typically dosed slightly higher in the mix than the maple fractions. Pre-seasonal build-up initiation (starting in summer or autumn before the March–May season) is preferred to reach maintenance before peak exposure. Spring pre-seasonal boosting may be recommended for missed maintenance doses before peak season.
Monthly maintenance injections continue for 3–5 years. The maintenance phase provides progressive immune tolerance, with most patients reporting meaningful symptom reduction during the second season of treatment. Annual spring pre-season immunotherapy boosting may be considered in some protocols.
After completing the full course, many patients maintain significant symptom reduction for several years. The absence of species-specific long-term discontinuation data for Acer pollen means clinical judgment guides re-evaluation. Some patients with persistent high exposure may benefit from extended maintenance.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Maple Boxelder SCIT
No published SCIT RCT has specifically evaluated maple-boxelder combined extract efficacy. Clinical practice extrapolates from general tree SCIT parameters and the documented asthma-hospitalization correlation with maple/box-elder pollen counts.
- Box-elder/maple pollen correlation with asthma hospitalizations (Dales 2008)60%Dales RE et al., Int Arch Allergy Immunol 2008;146:241 — Canadian city study correlating maple/box-elder counts with severe asthma ER visits and hospitalizations
- Maple-boxelder SCIT-specific RCT evidence0%No SCIT RCT identified for any Acer species SCIT through May 2026 — Cox 2011 JACI Practice Parameter; Greenhawt 2023 JTF update
- General tree pollen SCIT clinical practice efficacy (Cox 2011 Practice Parameter extrapolation)55%Cox L et al., J Allergy Clin Immunol 2011;127:S1 — general tree SCIT extrapolated framework; no Acer-specific data
Maple-boxelder SCIT has no species-specific RCT evidence. Clinical practice is guided by general tree SCIT principles (Cox 2011 JACI Practice Parameter), the documented asthma-hospitalization correlation establishing clinical magnitude (Dales 2008), and the incomplete intra-Acer cross-reactivity establishing the mix rationale over single-species alternatives. Patients should understand the evidence base before committing to a 3–5 year course.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Maple Boxelder SCIT Side Effects
Maple-boxelder SCIT side effects follow general tree pollen SCIT patterns with non-standardized extract variability.
Local reactions
4 documentedSystemic reactions
4 documentedSCIT carries a 30-minute observation period with epinephrine on hand; with Curex eligible patients self-administer at home, the serum is sterile-compounded to USP <797>, a prescribed epinephrine auto-injector is confirmed on hand, and the first dose plus every dose change are supervised live over Zoom. Pre-injection asthma assessment is recommended for patients with documented asthma. The non-standardized maple-boxelder extract increases variability in both efficacy and local reaction rates compared to FDA-standardized allergens.
SCIT vs Alternatives for Maple Boxelder
Spring Sapindaceae allergy patients have four main options: combined maple-boxelder SCIT — now available as an at-home weekly injection with Curex — sublingual drops, avoidance, or daily pharmacotherapy, all with the context that no RCT validates the maple-boxelder-specific SCIT approach. Curex at-home IgE testing covers box-elder and red maple as separate panel items, clarifying whether both species or only one drives sensitization before the combined-mix prescription is finalized.
| Criterion | Maple-Boxelder SCITBest | SLIT drops | Avoidance | Pharmacotherapy |
|---|---|---|---|---|
| Effectiveness | Moderate (extrapolated) | Moderate (less data for trees) | Partial only | Controls symptoms |
| 5-yr cost | $3,500–$8,000 | Varies by provider; sold as a general sublingual modality, not Curex's product | $0–$300/yr (HEPA) | $500–$2,000/yr |
| Duration | 3–5 years | 3–5 years | Ongoing | Indefinite |
| Convenience | At-home weekly self-injection with Curex (6 mo build-up); first dose and dose changes supervised live over Zoom | Daily at home | Lifestyle changes | Daily medication |
| Safety | USP <797> serum, Zoom-supervised dosing, prescribed epinephrine on hand, 30-min self-observation | Low systemic risk | Safest | Generally safe |
| Evidence level | No species-specific RCT | Limited tree SLIT RCT data | Reasonable | Standard of care |
Maple-Boxelder SCITBest
SLIT drops
Avoidance
Pharmacotherapy
Maple-boxelder SCIT is the pragmatic combined prescription for patients with confirmed Acer sensitization when testing shows both box-elder and maple sensitization or when the primary driver cannot be clearly separated. Curex at-home IgE testing covers box-elder and red maple as separate panel items — confirming which species actually drives sensitization — and eligible patients then self-administer that combined Acer shot at home for $129/month, with the serum sterile-compounded to USP <797>, a prescribed epinephrine auto-injector confirmed on hand, and the first dose plus every dose change supervised live over Zoom.
What Maple Boxelder SCIT Actually Costs
Most major insurers cover tree pollen SCIT when prescribed by a board-certified allergist with documented IgE sensitization. Maple-boxelder combined extract billing follows standard SCIT codes. Coverage verification before starting is recommended as prior authorization requirements vary by insurer.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your maple boxelder allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Maple Boxelder SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The combined maple-boxelder prescription exploits incomplete-but-substantial intra-Acer cross-reactivity to cover the full spring Sapindaceae pollen exposure profile in a single extract. Research (Dales et al. Int Arch Allergy Immunol 2008; Ipsen and Løwenstein cross-reactivity studies) shows that box-elder sensitization predicts reactivity to true maples, but the reverse is incomplete — patients sensitized primarily to red or silver maple do not always react to box-elder at equivalent degrees. This asymmetric cross-reactivity means a box-elder-only preparation might miss some maple-sensitized patients and vice versa. By combining both, allergists achieve broader Acer coverage in one prescription. The alternative — separate vials for each — increases injection complexity without a documented clinical benefit for most patients.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.